VEGF Polymorphisms and Colorectal Cancer Treatment
Author Information
Author(s): Loupakis Fotios, Ruzzo Annamaria, Salvatore Lisa, Cremolini Chiara, Masi Gianluca, Frumento Paolo, Schirripa Marta, Catalano Vincenzo, Galluccio Nadia, Canestrari Emanuele, Vincenzi Bruno, Santini Daniele, Bencardino Katia, Ricci Vincenzo, Manzoni Mariangela, Danova Marco, Tonini Giuseppe, Magnani Mauro, Falcone Alfredo, Graziano Francesco
Primary Institution: Università di Pisa, Italy
Hypothesis
Specific VEGF polymorphisms may affect the efficacy of bevacizumab in metastatic colorectal cancer patients.
Conclusion
VEGF -1498 C/T variants may help predict the efficacy of bevacizumab in treating metastatic colorectal cancer.
Supporting Evidence
- Patients with VEGF -1498 T/T genotype had significantly shorter progression-free survival.
- VEGF -1498 C/T variants were associated with treatment efficacy in the bevacizumab group.
- The study included a control group treated with FOLFIRI alone for comparison.
Takeaway
Doctors are trying to find out if certain genes can help predict how well a cancer treatment will work for patients.
Methodology
The study analyzed genomic DNA from 111 metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab, comparing results with a historical control group treated with FOLFIRI alone.
Potential Biases
The non-randomized comparison between treated and untreated patients may introduce bias.
Limitations
The study's retrospective design and non-randomized nature limit the applicability of the results.
Participant Demographics
Patients were consecutive metastatic colorectal cancer patients from 5 Italian Oncology Units.
Statistical Information
P-Value
p = 0.0046
Confidence Interval
[1.41-5.10]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website